Skip to main content
OpenTrials
Completed

NCT Number: NCT02805881

Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)

Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beer- Yakov Nees-Ziona Mental Health Center

Ness Ziona, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The subject is capable of understanding the study and to sign an informed consent.
  • Subject is between the ages of 18 to 65 years old.
  • Unipolar major depressive disorder
  • Score on the Hamilton Depression Rating Scale (HDRS21) > 22
  • Current MDD episode >3 months
  • Nonresponse with >6 week use of one to six antidepressant in current episode

Exclusion criteria

  • History of neurosurgical interventions.
  • Subjects with metal implants or shrapnel in their head, except for dental implants.
  • Skin lesion or inflammation at the region of the stimulating electrodes.
  • Pregnancy or Lactation.
  • Women of reproductive age not using efficient contraceptive method.
  • History of cerebrovascular event.
  • Psychotic or bipolar depression
  • History of schizophrenia, schizoaffective disorder or other non-mood disorder psychosis
  • Current delirium, dementia, amnestic disorder or other cognitive disorders
  • Clinically significant current suicidal intent as assessed by the investigator team.
  • Obsessive-compulsive disorder or post-traumatic stress disorder
  • Alcohol and non-alcohol psychoactive substance abuse or dependence
  • Significant cardiac, medical, or progressive neurological or medical illness
  • An implantable electrical device such as a pacemaker.

Treatment and study plan

Neurolief system

Device

Non-invasive cephalic neurostimulation device

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Time frame: 6 weeks

    Safety measures will be recorded and evaluated at every evaluation visit. It will be coded using the Medical Dictionary for Regulatory Activities. Vital signs (blood pressure and pulse) will be assessed and documented at each evaluation visit.

  2. Hamilton Depression Rating Scale (HDRS21)

    Time frame: 6 weeks

    Change in the total score on the Hamilton Depression Rating Scale (HDRS21) from baseline (visit 1) to week 6 (visit 4).

Sponsors and collaborators

Lead sponsor

Neurolief Ltd.

Industry

Registry information

Acronym: CTO-TNS

Important dates

Study start
2016
Primary completion
2021
Study completion
2021
First posted
Jun 20, 2016
Registry last updated
Sep 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.